Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth.

Galbally et al.

Looking through articles today at PubMed Health, a service of the United States National Library of Medicine and The National Institutes of Health, I found a piece titled “The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.” published by

In 2009, S. Alwan and J.M. Friedman, a research duo from the University of British Columbia in Vancouver, published a study titled “Safety of selective serotonin reuptake inhibitors in pregnancy.” in CNS Drugs that provided important insight into the link between gestational exposure to selective serotonin reuptake inhibitor drugs (such as Prozac,

In 2008, a team of Dutch researchers led by D.L. Van den Hove published a study in Neonatology titled “Prenatal maternal paroxetine treatment and neonatal mortality in the rat: a preliminary study.” evaluating the perinatal effects of gestational exposure to Paxil (paroxetine).

These researchers write, “Recent evidence has shown that prenatal maternal stress

Today, I came across an article from the March, 2011 edition of Journal of Population Therapeutics and Clinical Pharmacology titled “The effect of ascertainment bias in evaluating gestational antidepressant exposure.” that helps illustrate the link between gestational exposure to selective serotonin reuptake inhibitor drugs and birth defects, heart defects in particular.

Here is

Published in May, 2009 in Pharmacopsychiatry by a team of Australian researchers led by J. Rampono, an article titled “Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.” provides further evidence that drugs such as Celexa, Lexapro, Prozac, Paxil, Zoloft, Effexor and others may cross the placenta and affect a

Over the past several decades, a number of studies have linked Celexa exposure and birth defects.  This morning, I found several more, some of which are summarized below.  For more articles demonstrating the connection between birth defects and Celexa, follow the preceding link.

In a 2013 edition of Fetal and Pediatric Pathology,

In 2004, an article by B. Källén, a Swedish researcher, titled “Neonate characteristics after maternal use of antidepressants in late pregnancy.” in Archives of Pediatrics and Adolescent Medicine provides insight into the danger of perinatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs).

The stated objective was “To investigate neonatal outcomes in

In 2006, a team of Spanish medical researchers published a report titled “[Neonatal withdrawal syndrome to selective serotonin reuptake inhibitors: case report and literature review].” in Revista de Neurologica, wherein a child who suffered SSRI withdrawal symptoms after birth is presented along with a review of relevant literature.  “SSRI” stands for selective

A 2002 piece published by A.M. Costei and a team of medical researchers from Toronto in the medical journal Archives of Pediatrics and Adolescent Medicine tited “Perinatal outcome following third trimester exposure to paroxetine.” further demonstrates possible adverse effects of in utero exposure to Paxil.  (“Paroxetine” is the chemical name for Paxil,